Metabolic and immunological disturbances may be associated with hyperprolactinemia.
Aim: The aim of this study was examination the presence of some metabolic and immunological disturbances, like as the changes in and body composition, as risk factors for development of atherosclerosis, in young women with hyperprolactinemia.
Material and methods: The investigation was performed as prospective study in a group of 20 premenopausal women with prolactinomas. The serum levels of prolactin, lipids and fibrinogen were measured, like as body mass index and body composition by bioelectric impedance. The examination was performed before and after therapy by dopamine agonists that examination group was control itself.
Results: The mean values of serum prolactin were significantly higher before therapy (171.89±131.59 versus 14.01±10.35 ng/ml; P <0.000). Achievement of normoprolactinemia was followed by non significant reduction of body mass index and body fat. The significant decreases of total cholesterol (5.22±0.99 versus 4.57±0.88 mmol/l; P< 0.03), LDL cholesterol (3.34±0.90 versus 2.81±0.57 mmol/l; P<0.012) and non HDL cholesterol (3.82±1.03 versus 3.25±0.71 mmol/l; P<0.006) were present after treatment of hyperprolactinemia. The reduction of triglyceride levels in normoproalcinemic state was non significant. The fibrinogen was only slightly increased before treatment.
Conclusion: These results suggest of the possible influence of hyperprolactinemia for development accelerated atherosclerosis. Treatment of hyperprolactinemia could be useful in prevention of atherosclerosis in young women.
Prague, Czech Republic
24 - 28 Apr 2010
European Society of Endocrinology